Trial · NCT02759575
A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
NCT02759575, Phase 1, Phase 2, Completed, Vinita Takiar; results first posted 2021-03-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma. Trials, record NCT02759575. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02759575
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
- NCT number
- NCT02759575
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 9 participants, actual
- Lead sponsor
- Vinita Takiar
- Conditions
- Head and Neck Cancer
- Interventions
- Pembrolizumab, Radiation Therapy, Cisplatin
- First posted
- 2016-05-03
- Last updated
- 2021-03-12
- Results first posted
- 2021-03-12
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Treatment-Related Grade 3 or 4 Adverse Events as Assessed by CTCAE V4.0 | 30 days following completion of treatment for the first 6 participants | Greater than 2 grade 3 or 4 adverse events that are definitely, probably or possibly related to the pembrolizumab in the first cohort of 6 participants |
| Primary | Laryngectomy-free Survival in Locally Advanced Laryngeal Squamous Cell Carcinoma | 18 months | This is the number of subjects that are laryngectomy-free at 18 months. |
| Secondary | Laryngectomy-free Survival in Locally Advanced Laryngeal Squamous Cell Carcinoma | 12 months | This is the number of subjects that are laryngectomy-free at 12 months. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Treatment-Related Grade 3 or 4 Adverse Events as Assessed by CTCAE V4.0 | 30 days following completion of treatment for the first 6 participants | These are the first six participants that completed the study. | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Laryngectomy-free Survival in Locally Advanced Laryngeal Squamous Cell Carcinoma | 18 months | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Laryngectomy-free Survival in Locally Advanced Laryngeal Squamous Cell Carcinoma | 12 months | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Related Grade 3 or 4 Adverse Events as Assessed by CTCAE V4.0 | Pembrolizumab | 2 | Participants | ||
| Laryngectomy-free Survival in Locally Advanced Laryngeal Squamous Cell Carcinoma | Pembrolizumab | 9 | Participants | ||
| Laryngectomy-free Survival in Locally Advanced Laryngeal Squamous Cell Carcinoma | Pembrolizumab | 9 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pembrolizumab | 9 | |
| Overall Study | COMPLETED | Pembrolizumab | 9 | |
| Overall Study | NOT COMPLETED | Pembrolizumab | 0 |
Source ClinicalTrials.gov
Adverse events87
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Acute Kidney Injury | Renal and urinary disorders | Pembrolizumab | 4 | 9 | 6 |
| other | Anemia | Blood and lymphatic system disorders | Pembrolizumab | 3 | 9 | 5 |
| other | Anxiety | Psychiatric disorders | Pembrolizumab | 3 | 9 | 3 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Pembrolizumab | 1 | 9 | 1 |
| other | Colitis | Gastrointestinal disorders | Pembrolizumab | 1 | 9 | 1 |
| other | Constipation | Gastrointestinal disorders | Pembrolizumab | 3 | 9 | 4 |
| other | Cough | Respiratory, thoracic and mediastinal disorders | Pembrolizumab | 4 | 9 | 4 |
| other | Creatinine increased | Investigations | Pembrolizumab | 1 | 9 | 2 |
| other | Dehydration | Metabolism and nutrition disorders | Pembrolizumab | 3 | 9 | 4 |
| other | Dermatitis radiation | Injury, poisoning and procedural complications | Pembrolizumab | 9 | 9 | 12 |
1 to 10 of 87Source ClinicalTrials.gov
See all 87 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pembrolizumab | 3 | 9 |
| Total, other adverse events | Pembrolizumab | 9 | 9 |
| Total, serious adverse events | Pembrolizumab | 3 | 9 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 35434343 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02759575
GET https://conductscience.org/api/trials/v1/NCT02759575/events?page=2